PYPD
NASDAQ HealthcarePolyPid Ltd. - Ordinary Shares
Biotechnology
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
๐ Market Data
| Price | $5.19 |
|---|---|
| Volume | 183,837 |
| Market Cap | 99.51M |
| Beta | 1.400 |
| RSI (14-Day) | 62.1 |
| 200-Day MA | $4.29 |
| 50-Day MA | $4.81 |
| 52-Week High | $5.62 |
| 52-Week Low | $3.06 |
| Forward P/E | -4.14 |
| Price / Book | 11.33 |
๐ฏ Investment Strategy Scores
PYPD scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (69/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PYPD in your text
Paste any article, transcript, or post โ the tool will extract PYPD and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.